This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfyffer, G. E.
Right arrow Articles by Rüsch-Gerdes, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfyffer, G. E.
Right arrow Articles by Rüsch-Gerdes, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2002, p. 1670-1674, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1670-1674.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Testing of Susceptibility of Mycobacterium tuberculosis to Pyrazinamide with the Nonradiometric BACTEC MGIT 960 System

Gaby E. Pfyffer,1* Frantiska Palicova,1 and Sabine Rüsch-Gerdes2

Swiss National Center for Mycobacteria, Department of Medical Microbiology, University of Zurich, 8028 Zurich, Switzerland,1 National Reference Center for Mycobacteria, Forschungszentrum Borstel, D-23845 Borstel, Germany2

Received 19 December 2001/ Returned for modification 22 January 2002/ Accepted 12 February 2002

The reliability of the novel BACTEC MGIT 960 pyrazinamide (PZA) kit (Becton Dickinson Microbiology Systems, Sparks, Md.) was assessed for testing of susceptibility of Mycobacterium tuberculosis to PZA. Results generated by the BACTEC MGIT 960 system (Becton Dickinson) were compared with those obtained with the BACTEC 460TB system. Extensive proficiency testing (phase I) and reproducibility testing (phase II) as well as susceptibility testing of blinded strains of M. tuberculosis from the Centers for Disease Control and Prevention (phase III) were performed prior to testing 58 strains isolated from clinical specimens (phase IV). After resolution of discrepant results obtained by the two BACTEC methods by two other laboratories which acted as independent arbiters (phase V), overall agreement of the BACTEC MGIT 960 system with the BACTEC 460TB system for PZA testing of phase IV strains was 96.6%. Between the two systems there was no statistically significant difference in time until results were obtained, i.e., 6.8 days (BACTEC MGIT 960) versus 5.4 days (BACTEC 460TB), the latter not counting the time required for a subculture with a growth index of 200, however. The new BACTEC MGIT PZA susceptibility testing procedure works equally well for inocula prepared from liquid (MGIT) and solid (Löwenstein-Jensen) cultures. PZA MGIT medium in plastic tubes yielded results equivalent to medium dispensed in glass tubes.

* Corresponding author. Mailing address: Swiss National Center for Mycobacteria, Department of Medical Microbiology, University of Zurich, Gloriastrasse 30, 8028 Zurich, Switzerland. Phone: 41 1 634 27 86. Fax: 41 1 634 49 18. E-mail: pfyffer{at}immv.unizh.ch.

Journal of Clinical Microbiology, May 2002, p. 1670-1674, Vol. 40, No. 5
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.5.1670-1674.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Upton, A., Woodhouse, A., Vaughan, R., Newton, S., Ellis-Pegler, R. (2009). Evolution of Central Nervous System Multidrug-Resistant Mycobacterium tuberculosis and Late Relapse of Cryptic Prosthetic Hip Joint Tuberculosis: Complications during Treatment of Disseminated Isoniazid-Resistant Tuberculosis in an Immunocompromised Host. J. Clin. Microbiol. 47: 507-510 [Abstract] [Full Text]  
  • Sekiguchi, J.-I., Nakamura, T., Miyoshi-Akiyama, T., Kirikae, F., Kobayashi, I., Augustynowicz-Kopec, E., Zwolska, Z., Morita, K., Suetake, T., Yoshida, H., Kato, S., Mori, T., Kirikae, T. (2007). Development and Evaluation of a Line Probe Assay for Rapid Identification of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Strains. J. Clin. Microbiol. 45: 2802-2807 [Abstract] [Full Text]  
  • Singh, P., Wesley, C., Jadaun, G. P. S., Malonia, S. K., Das, R., Upadhyay, P., Faujdar, J., Sharma, P., Gupta, P., Mishra, A. K., Singh, K., Chauhan, D. S., Sharma, V. D., Gupta, U. D., Venkatesan, K., Katoch, V. M. (2007). Comparative Evaluation of Lowenstein-Jensen Proportion Method, BacT/ALERT 3D System, and Enzymatic Pyrazinamidase Assay for Pyrazinamide Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 45: 76-80 [Abstract] [Full Text]  
  • Martin, A., Takiff, H., Vandamme, P., Swings, J., Palomino, J. C., Portaels, F. (2006). A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 58: 327-331 [Abstract] [Full Text]  
  • Rusch-Gerdes, S., Pfyffer, G. E., Casal, M., Chadwick, M., Siddiqi, S. (2006). Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials.. J. Clin. Microbiol. 44: 688-692 [Abstract] [Full Text]  
  • Piersimoni, C., Olivieri, A., Benacchio, L., Scarparo, C. (2006). Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems. J. Clin. Microbiol. 44: 20-28 [Full Text]  
  • Richter, E., Weizenegger, M., Fahr, A.-M., Rusch-Gerdes, S. (2004). Usefulness of the GenoType MTBC Assay for Differentiating Species of the Mycobacterium tuberculosis Complex in Cultures Obtained from Clinical Specimens. J. Clin. Microbiol. 42: 4303-4306 [Abstract] [Full Text]  
  • Huang, T.-S., Lee, S. S.-J., Tu, H.-Z., Huang, W.-K., Chen, Y.-S., Huang, C.-K., Wann, S.-R., Lin, H.-H., Liu, Y.-C. (2004). Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide. J Antimicrob Chemother 53: 600-603 [Abstract] [Full Text]  
  • Bemer, P., Bodmer, T., Munzinger, J., Perrin, M., Vincent, V., Drugeon, H. (2004). Multicenter Evaluation of the MB/BACT System for Susceptibility Testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 42: 1030-1034 [Abstract] [Full Text]  
  • Scarparo, C., Ricordi, P., Ruggiero, G., Piccoli, P. (2004). Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method. J. Clin. Microbiol. 42: 1109-1114 [Abstract] [Full Text]  
  • Huang, T.-S., Lee, S. S.-J., Tu, H.-Z., Huang, W.-K., Chen, Y.-S., Huang, C.-K., Wann, S.-R., Lin, H.-H., Liu, Y.-C. (2003). Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan. Antimicrob. Agents Chemother. 47: 3672-3673 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»